36 results
424B5
MAIA
MAIA Biotechnology Inc
14 Feb 24
Prospectus supplement for primary offering
5:18pm
. Himmelreich acted as the Company’s Director of Accounting and Financial Reporting, where he provided oversight for the Company’s filings with the U.S
424B5
MAIA
MAIA Biotechnology Inc
17 Nov 23
Prospectus supplement for primary offering
9:06am
Director of Accounting and Financial Reporting, where he provided oversight for the Company’s filings with the U.S. Securities and Exchange Commission
8-K
MAIA
MAIA Biotechnology Inc
15 Nov 23
Termination of a Material Definitive Agreement
8:42am
Director of Accounting and Financial Reporting, where he provided oversight for the Company’s filings with the U.S. Securities and Exchange Commission (“SEC
8-K
EX-10.1
muuxz qtz0ek2
1 Sep 23
Entry into a Material Definitive Agreement
4:45pm
DRS
nnxsksu kb8uz5ojv79
1 Jun 23
Draft registration statement
12:00am
8-K
EX-1.1
v4m c5d3d9xz
27 Apr 23
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
5:25pm
424B4
1e8n9i0a 6dz3re7bp
25 Apr 23
Prospectus supplement with pricing info
7:45pm
DEF 14A
a04188bbm5udjrgnnlak
19 Apr 23
Definitive proxy
4:06pm
DRS
dr5rbdr
23 Dec 22
Draft registration statement
12:00am
8-K
EX-1.1
l7fk33jrll66p5xwgs
1 Aug 22
MAIA Biotechnology Announces Pricing of Initial Public Offering
4:05pm
424B4
z83lguo1
29 Jul 22
Prospectus supplement with pricing info
8:31am